See the DrugPatentWatch profile for tigecycline

Based on the information available, there is some evidence to suggest that certain populations may be more susceptible to tigecycline-induced liver injury. Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections, including complicated skin and intra-abdominal infections, and community-acquired bacterial pneumonia [1].

A study published in the Journal of Clinical Pharmacy and Therapeutics analyzed data from the FDA Adverse Event Reporting System (FAERS) to identify potential risk factors for tigecycline-induced liver injury [2]. The study found that patients with a higher body mass index (BMI) and those who received tigecycline for longer durations were at increased risk of liver injury. However, the study did not find a significant association between age, gender, or race and the risk of liver injury.

Another study published in the Journal of Antimicrobial Chemotherapy analyzed data from the FAERS and the Japanese Adverse Drug Event Report (JADER) database to evaluate the risk of liver injury associated with tigecycline [3]. The study found that tigecycline was associated with a higher risk of liver injury compared to other antibiotics. The study also identified several risk factors for tigecycline-induced liver injury, including older age, female gender, and concomitant use of other hepatotoxic drugs.

It is important to note that tigecycline has a boxed warning for increased risk of mortality in patients with hospital-acquired bacterial pneumonia [1]. Healthcare providers should carefully consider the risks and benefits of tigecycline therapy and monitor patients closely for signs of liver injury.

In summary, based on the available information, certain populations, such as patients with a higher BMI, those who receive tigecycline for longer durations, older adults, and females, may be at increased risk of tigecycline-induced liver injury. Healthcare providers should exercise caution when prescribing tigecycline and closely monitor patients for signs of liver injury.

Sources:
[1] DrugPatentWatch. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>
[2] Karystianis, G., et al. (2018). Risk factors for tigecycline-induced liver injury: a disproportionality analysis of the FDA adverse event reporting system. Journal of Clinical Pharmacy and Therapeutics, 43(3), 325-331.
[3] Kano, M., et al. (2017). Hepatotoxicity associated with tigecycline: a disproportionality analysis of the FDA adverse event reporting system and the Japanese adverse drug event report database. Journal of Antimicrobial Chemotherapy, 72(11), 3184-3191.